Yeryoy navigation

Best Practices for the Medical Oncology Boards

Survival benefit was observed in heavily pretreated populations, including those who progressed after checkpoint inhibition and antibody drug conjugates.

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD

Advancing Treatment for EGFR Inhibitor-Associated Dermal Toxicities

A group of clinicians gives study advice on how to best prepare for the medical oncology board exams.

ATR04-484 showed inhibition of both methicillin-sensitive and methicillin-resistant Staphylococcus aureus bacteria strains, which are associated with rash.

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

ATR04-484 showed inhibition of both methicillin-sensitive and methicillin-resistant Staphylococcus aureus bacteria strains, which are associated with rash.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS

July 3rd 2025

12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

Diana Kantarovich;Olutayo Sogunro;Christopher Umbricht;Catherine E. Klein, MD;James White;Mehran Habibi

Patient Enrollment for Phase 3 UGN-103 Trial in LG-IM-NMIBC Complete

The phase 3 UTOPIA trial has enrolled a total of 99 patients with low-grade intermediate-risk NMIBC to receive UGN-103.

Tim Cortese

Bria-IMT Yields Updated Survival Benefit in Metastatic Breast Cancer

The phase 3 UTOPIA trial has enrolled a total of 99 patients with low-grade intermediate-risk NMIBC to receive UGN-103.

Related Content

Best Practices for the Medical Oncology Boards

Survival benefit was observed in heavily pretreated populations, including those who progressed after checkpoint inhibition and antibody drug conjugates.

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD

Advancing Treatment for EGFR Inhibitor-Associated Dermal Toxicities

A group of clinicians gives study advice on how to best prepare for the medical oncology board exams.

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

ATR04-484 showed inhibition of both methicillin-sensitive and methicillin-resistant Staphylococcus aureus bacteria strains, which are associated with rash.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS

July 3rd 2025

12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

Diana Kantarovich;Olutayo Sogunro;Christopher Umbricht;Catherine E. Klein, MD;James White;Mehran Habibi

Patient Enrollment for Phase 3 UGN-103 Trial in LG-IM-NMIBC Complete

Tim Cortese